The primary objective in the biotechnology and pharmaceutical industry is to be the first market provider with a new therapeutic entity, the first to achieve maximum market penetration, and the first to create barriers to competition to be assured of freedom to operate.

Because the success of biotechnology companies today depends on their ability to transfer biotechnology and intellectual property rights for appropriate value, partnering relationships between pharmaceutical and biotechnology companies continue to increase. Licensing, with its flexibility and inclusion of provisions pertaining to improvements and patents, is uniquely suited to facilitate these transfers.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]